CombiGene’s and Neurochase’s preclinical study provides valuable information for the upcoming long-term studies in toxicology and biodistribution STOCKHOLM — On June 28, 2021, CombiGene (“CombiGene”, “the Company”) announced that the [...]
As gene therapy pioneers begin to tackle systemic diseases and those with a large patient cohort, their focus must increasingly be set on the twin goals of exceptional AAV yields [...]
